Format

Send to

Choose Destination
Cancer Cell. 2008 Oct 7;14(4):285-98. doi: 10.1016/j.ccr.2008.09.002.

A short Nur77-derived peptide converts Bcl-2 from a protector to a killer.

Author information

1
Cancer Center, Burnham Institute for Medical Research, La Jolla, CA 92037, USA.

Abstract

Bcl-2 can be converted into a proapoptotic molecule by nuclear receptor Nur77. However, the development of Bcl-2 converters as anticancer therapeutics has not been explored. Here we report the identification of a Nur77-derived Bcl-2-converting peptide with 9 amino acids (NuBCP-9) and its enantiomer, which induce apoptosis of cancer cells in vitro and in animals. The apoptotic effect of NuBCPs and their activation of Bax are not inhibited but rather potentiated by Bcl-2. NuBCP-9 and its enantiomer bind to the Bcl-2 loop, which shares the characteristics of structurally adaptable regions with many cancer-associated and signaling proteins. NuBCP-9s act as molecular switches to dislodge the Bcl-2 BH4 domain, exposing its BH3 domain, which in turn blocks the activity of antiapoptotic Bcl-X(L).

PMID:
18835031
PMCID:
PMC2667967
DOI:
10.1016/j.ccr.2008.09.002
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Grant support

Publication types

MeSH terms

Substances

Grant support

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center